Article

Mapping the Modification Landscape of MHC-I Epitopes: A Framework for Immunogenic Peptidomimetic Antigen Design

2026-03-10

Abstract excerpt

<h4>ABSTRACT</h4> Peptide-based cancer vaccines offer a promising strategy to target tumor-specific neoantigens. This approach is increasingly critical as post-translationally modified peptides, driven by altered tumor metabolism, emerge as a unique class of neoantigens. Because these chemically distinct epitopes cannot be genetically encoded by mRNA or viral platforms, synthetic peptide vaccines are poised to be...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 76095530-80fa-53a5-ae23-6087377fede1
DOI: 10.64898/2026.03.06.710184

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mapping the Modification Landscape of MHC-I Epitopes: A Framework for Immunogenic Peptidomimetic Antigen DesignDOI 10.64898/2026.03.06.710184Read

Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development.Semantic proximity Read

Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.Semantic proximity Read

Multi-strategies embedded framework for neoantigen vaccine maturationSemantic proximity Read

IMPACT - Phase Ib Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell CarcinomaSemantic proximity Read

Anticancer Peptides: Design Principles, Translational Bottlenecks, and Emerging OpportunitiesSemantic proximity Read

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionSemantic proximity Read

Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical ProgressSemantic proximity Read

A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for CancerSemantic proximity Read

Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors.Semantic proximity Read

A generalizable system for antigenic peptide targeting across HLA-I allotypesSemantic proximity Read

Targeting peptide antigens using a multiallelic MHC I-binding system.Semantic proximity Read

A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor ChallengeSemantic proximity Read